Research Article

Evaluation of a microRNA-based Risk Classifier Predict-2 ing Cancer-Specific Survival in Renal Cell Carcinoma with 3 Tumor Thrombus of the Inferior Vena Cava 4

Mischa J. Kotlyar^{1, †}, Markus Krebs^{2, †}, Maximilian Burger³, Hubert Kübler¹, Ralf Bargou², Susanne Kneitz⁴, Wolfgang Otto³, Johannes Breyer³, Daniel C. Vergho³, Burkhard Kneitz¹, Charis Kalogirou ^{1, *}

Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany

Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany

Department of Urology, Caritas St. Josef and University of Regensburg Medical Center, 93053 Regensburg, Germanv

4 Physiological Chemistry I, Biocenter, University of Würzburg, 97074 Würzburg, Germany

† These authors contributed equally to this work.

Correspondence: kalogirou c@ukw.de; Tel.: +49 931 201 32001

Abstract: (1) Background: Clear cell renal cell carcinoma extending into the inferior vena cava 16 (ccRCC^{IVC}) represents a clinical high-risk setting. However, there is substantial heterogeneity within 17 this patient subgroup regarding survival outcomes. Previously, members of our group developed a 18 microRNA(miR)-based risk classifier - containing miR-21, miR-126 and miR-221 expression - which 19 significantly predicted cancer-specific survival (CSS) of ccRCC^{IVC} patients. (2) Methods: Examining 20 a single-center cohort of tumor tissue from n = 56 patients with ccRCC^{IVC}, we measured expression 21 levels of miR-21, miR-126 and miR-221 by qRT-PCR. Prognostic impact of clinicopathological pa-22 rameters and miR expression were investigated via univariate and multivariate cox regression. Re-23 ferring to the previously established risk classifier, we performed Kaplan Meier analyses for single 24 miR expression levels and the combined risk classifier. Cut-off values and weights within the risk 25 classifier were taken from the previous study. (3) Results: miR-21 and miR-126 expression were sig-26 nificantly associated with lymphonodal status at time of surgery, development of metastasis during 27 follow-up, and cancer-related death. In Kaplan Meier analyses, miR-21 and miR-126 significantly im-28 pacted CSS in our cohort. Moreover, applying the miR-based risk classifier significantly stratified 29 ccRCC^{IVC} according to CSS. (4) Conclusions: In our retrospective analysis, we successfully validated 30 the miR-based risk classifier within an independent ccRCC^{IVC} cohort. 31

Keywords: kidney cancer; RCC; venous infiltration; biomarker; cancer-specific survival; miR; risk stratification 32

33

1

5

6

7

8

9

10

11

12 13

14

15

34

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1. Introduction

In about 10% of all cases, clear cell renal cell carcinomas (ccRCC) extend into the inferior vena 36 cava (ccRCC^{IVC}) [1–3]. While constituting a high-risk setting in general, there still is substantial clinical 37 heterogeneity within the ccRCC^{IVC} subgroup – with reported 5-year survival rates ranging from 37% 38 to 65% for non-metastasized patients treated with nephrectomy in combination with tumor throm-39 bectomy [4-9]. Regarding this discrepancy, biomarkers are urgently needed to identify patients with 40 a specifically high risk of cancer relapse [10,11]. Potentially, ccRCC^{IVC} patients may also benefit from 41 adjuvant systemic therapy and an intensified follow-up. 42

MicroRNAs (miRs) as biomarker candidates are post-transcriptional regulators of gene expres-43 sion in various cancer entities [12-14]. Regarding ccRCC, several studies demonstrated the prog-44 nostic impact of miR expression levels in tumor tissue [15-17]. Previously, Vergho et al. established 45 a combined risk classifier for patients with ccRCC^{IVC} receiving nephrectomy and thrombectomy in 46 curative intention [10]. Based on miR-21, miR-126 and miR-221 expression in tumor tissue, the risk 47 classifier significantly stratified patients regarding cancer-specific survival (CSS) in a single-center 48 cohort (n = 37) – with a 5-year CSS of 78% vs. 18% in the favorable compared to the unfavorable 49 subgroup [10]. 50

To further assess the miR-based risk classifier as a prognostic tool in ccRCC^{IVC} patients, we 51 retrospectively evaluated it within an independent cohort (n = 56) from the Department of Urology, 52 University of Regensburg (Regensburg, Germany). Cut-off values for miR expression levels as well 53 as internal classifier weights were transferred from the previous pilot study [10], in order to test its 54 transferability to independent study cohorts. Figure 1 illustrates the course of our study. 55



Figure 1. Course of the study - using a microRNA (miR)-based risk classifier established previously [10], we 56 examined the prognostic impact of miR-21, miR-126, and miR-221 expression in an independent cohort of clear 57 cell renal cell carcinoma samples with infiltration of the inferior vena cava (ccRCC^{IVC}; n = 54). To assess the 58 transferability of the miR-based risk classifier, cut-off value and weights were identical to the previous study. 59

60

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

2. Materials and Methods

2.1. Tumor Tissue Samples and Patients

Paraffin-embedded primary ccRCC^{IVC} tumor-samples of 56 subjects who underwent radical sur-64 gery were aggregated by the Department of Urology, University of Regensburg, Germany (1997-65 2006). A uropathologist selected sample-regions with > 90% cancerous tissue. Follow-up data were 66 collected by the Department of Urology, University of Regensburg (Regensburg, Germany). The 67 study was approved by the local Ethics Committee (Regensburg: Nr. 08/108). Detailed characteristics 68 of the study cohort are summarized in Table 1. 69

2.2. RNA Extraction and gRT-PCR

Using the RecoverAll[™] Total Nucleic Acid Isolation Kit (Thermo Fisher Scientific, Waltham, MA), 71 total RNA from paraffin-embedded samples was isolated according to the manufacturer's instructions. 72 RNA concentration and 260/280 ratio were analyzed by Spark® 10M (TECAN, Männedorf, Switzer-73 land). cDNA was synthesized from total RNA with stem-loop reverse transcription primers (TaqMan 74 microRNA Assay protocol, Applied Biosystems, Birchwood, UK). TaqMan microRNA Assay kit was 75 used to quantify miR expression according to manufacturer's protocols. Samples showing a standard 76 deviation > 0.5 were excluded (all reactions performed in triplicates). Small nuclear RNA (RNU6B) 77 expression was used for normalization of miRs relative expression values. Samples with expression 78 levels of RNU6B > 30 Ct were excluded from further analyses. Relative miR expressions were calcu-79 lated using the Δ Ct-method (Δ Ct sample = Ct miR of interest – Ct RNU6B). To calculate fold changes 80 in miR expression between samples, we used the 2AACt method (in this study, referred to as the 81 $\Delta\Delta$ Ct method). 82

2.3 Statistics and computational analysis

A Jupyter Notebook environment (version 6.3.0) was used to perform all statistical analyses us-84 ing Python version 3.8.8, LifeLines version 0.27.0 [18], Pandas version 1.2.4 [19], Matplotlib 3.3.4 85 [20], Scipy version 1.6.2 [21]. 86

To analyze differences between miR expression levels, we used Student's t-test for normally 87 distributed data with similar variance - otherwise, Mann-Whitney-U-Test was applied. Data distribu-88 tion and variance were assessed via Shapiro Wilk and Levene test, respectively. A significance level 89 of 0.05 was applied. 90

2.3.1 Validation of microRNA-based Risk Classifier

To evaluate the validity of the miR-based risk classifier – (4.592 × Δ Ct miR-21) + (-3.892 × Δ Ct 92 miR-126) + (-1.938 × Δ Ct miR-221) – weights and cut-off values (\geq 18.7 Δ Ct = "unfavorable sub-93 group", < 18.7 Δ Ct = "favorable subgroup") were transferred from the pilot study [10] and applied in 94 order to stratify the ccRCC^{IVC} study cohort from Regensburg and perform Kaplan-Meier analyses. 95 Within the risk classifier formula, a negative factor indicates that higher expression levels correlate 96 with longer survival, while a positive factor correlates with shorter survival. For further analysis, we 97 transferred cut-off values for miR-21 (8.17 ΔCt), miR-126 (3.57 ΔCt) and miR-221 expression (1.84 98 Δ Ct) to evaluate their predictive potential in the new cohort using the Kaplan-Meier survival analysis. 99

2.3.2 microRNA-based Risk Classifier Calculation

Referring to the pilot study by Vergho et al. [22], the risk classifier was calculated as follows:

1. Performing uni- and multivariate Cox regression analysis, Vergho et al. evaluated the impact of 102 clinicopathological parameters and various miRs on CSS. 103

62

63

70

83

91

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

4 of 13

- To select the best fitting Cox model, the relative goodness-of-fit was measured based on the 104 Akaike information criterion. The combination of miR-21, -126 and -221 displayed the best prediction properties.
- 3. Finally, the miR-based risk classifier was calculated based on the publication by Lossos et al. 107 [23]. Hereby, a factor attained from the Cox model's z-score was identified for miR-21, -126 and -221. In the next step, relative expression levels (ΔCt) of miRs were multiplied by these factors 109 (weights) using the formula (4.592 × ΔCt miR-21) + (-3.892 × ΔCt miR-126) + (-1.938 × ΔCt 110 miR-221). Risk score cut-off (18.7 ΔCt) was determined by ROC. 111

3. Results

112

Table 1 summarizes the basic clinical and pathological characteristics of our study cohort. De-113tailed follow-up information was available for 54 of 56 patients suffering from ccRCC^{IVC} (96.4%).114

Table 1. Clinical and pathological patient characteristics (n = 56). Detailed follow-up information was available115for 54 patients.116

Characteristics				
Median Follow-up	94 (1 – 190) months			
Median Age	67 (41 – 89) years			
Sex				
female	22 (39.3%)			
male	34 (60.7%)			
Tumor Stage: pT3b	56 (100%)			
Fuhrman Grade				
G2	41 (73.2%)			
G3	15 (26.8%)			
Nodal Status				
NO	45 (80.4%)			
N+	11 (19.6%)			
Distant Metastasis during Follow-up				
MO	35 (62.5%)			
M1	21 (37.5%)			
Median Tumor Size	70 (18 – 225) mm			
Overall survival				
yes	27 (48.2%)			
no	29 (51.8%)			
Cancer-related death				
yes	13 (23.2%)			
no	43 (76.8%)			

3.1. Association of miR-21, -126 and -221 Expression with Clinicopathological Characteristics 118

To investigate the impact of miR-21, -126 and -221 within our ccRCC^{IVC} cohort, we associated 119 expression levels of miR-21, miR-126 and miR-221 to relevant clinical parameters. Figure 2 illustrates 120 the results. 121

At time of surgery, 11 of 56 ccRCC^{IVC} patients (19.6%) were diagnosed with nodal metastasis. 122 In cases with positive nodal status, a trend towards up-regulation of miR-21 (p = 0.065) and a signif-123 icant down-regulation of miR-126 (p < 0.01) were observed. For miR-221, there was no statistically 124 significant association to nodal status. 125

During the follow-up period, distant metastasis emerged in 21 of 56 ccRCC^{IVC} patients (37.5%). 126 As shown in Figure 2b, we observed a significant up-regulation of miR-21 (p < 0.01) and down-regu-127 lation of miR-126 (p < 0.001) as well as a trend towards downregulation for miR-221 (p = 0.06) in 128 ccRCC^{IVC} samples of patients with metastasized disease. 129

Of 56 patients with ccRCC^{IVC}, 13 (23.2%) died during the follow-up period due to cancer (cancer-130 related death, CRD). Regarding miR expression levels, we found a significant up-regulation of miR-131 21 (p < 0.001) and a down-regulation of miR-126 (p < 0.01) in CRD cases. Instead, miR-221 expres-132 sion did not show a statistically significant association to CRD in this analysis (p = 0.27). 133



Figure 2. miR-21, -126 and -221 expression levels depending on lymphonodal status (a), distant metastases (b) 134 and cancer-related death (CRD, c). Significant changes between subgroups were calculated using unpaired 135 Student's t test (CRD: miR-221; nodal status: miR-21, -221; distant metastases: miR-21, -126) or Mann-Whitney-136 U test (CRD: miR-21, -126; nodal status: miR-126; distant metastases: miR-221). $p < 0.05^{\circ}$; $p < 0.01^{\circ}$ 137 0.001 ***. 138

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

140

3.2. Cox regression Analysis

Next, we performed a univariate Cox regression analysis to further assess the prognostic potential of miR-21, -126, and -221 expression levels as predictors of CRD. Detailed follow-up information was available for 54 of 56 cases with a median of 94 months.

As summarized in Table 2a, miR-21 and miR-126 significantly predicted the occurrence of CRD 144 in our study cohort (p = 0.003, Hazard Ratio (HR) 3.79 for miR-21, p = 0.00003, HR 0.19 for miR-126). In contrast, miR-221 expression in tumor tissue did not display significant prognostic potential 146 (p = 0.22). Regarding further clinical parameters, significant results were also observed for nodal 147 involvement, metastatic status and Fuhrman grade. 148

Additionally, as shown in Table 2b, we performed a multivariate Cox regression to investigate if 149 the miR candidates remain acting as relevant predictors of CRD within our ccRCC^{IVC} cohort in attendance of nodal involvement and Fuhrman grade. Also under this conditions miR-21 and miR-126 significantly predicted the occurrence of CRD (p = 0.02, HR 4.94 for miR-21, p = 0.01, HR 0.27 for miR-126). MiR-221 expression again did not meet statistical significance as predictor of CRD (p = 0.12) (Table 2 and Figure 3d). No significant results were observed for the clinical parameters nodal involvement (p = 0.71) and Fuhrman grade (p = 0.13).

Table 2. (a) Univariate Cox regression of ccRCCIVC patients for miR expression levels and clinicopathological156parameters, (b) multivariate Cox regression for miR expression levels as well as Nodal Status and Fuhrman157Grade. 95% Confidence intervals (CI) shown for Hazard ratios (HR). p values were computed using the chi-158squared test. $p < 0.05^*$; $p < 0.01^{**}$; $p < 0.001^{***}$.159

	Cancer-related death			
	Univariate analys	sis	(b) Multivariate analysis	
Parameters	HR (95% CI)	<i>p</i> value	HR (95% CI)	p value
miR-21	3.79 (1.55 – 9.26)	0.003**	4.94 (1.29 – 18.98)	0.02*
miR-126	0.19 (0.09 – 0.42)	0.00003***	0.27 (0.097 – 0.75)	0.01*
miR-221	0.74 (0.46 – 1.19)	0.22	0.64 (0.37 – 1.12)	0.12
Age	0.98 (0.92 – 1.03)	0.42		
Sex	2.10 (0.58 – 7.65)	0.26		
Tumor size	1.01 (1.00 – 1.03)	0.07		
Fuhrman Grade	3.79 (1.27 – 11.33)	0.02*	3.28 (0.70 – 15.32)	0.13
Nodal status	6.70 (2.09 – 21.47)	0.001**	1.34 (0.29 – 6.12)	0.71
Distant metastasis	∞	NA		

Abbreviation: CI, confidence interval; HR, hazard ratio; ∞ / NA: In case of distant metastasis as predictor of CRD, the coefficient was not estimable (positively infinite). HR and *p* values were therefore not shown.

To further understand and illustrate the prognostic impact of single miRNAs on CSS (based on 161 previously fitted multivariate Cox regression model), we plotted survival curves according to isolated 162 miR expression levels (Figure 3a-c). For miR-21, higher relative expression levels were associated 163 with lower CSS (Figure 3a). In contrast, higher expression levels of miR-126 as well as miR-221 were 164 associated with higher CSS (Figure 3b, c). 165



Figure 3. (a-c) Survival curves for varying miR expression levels of miR-21, -126, -221 (based on fitted multi-166 variate Cox regression model), illustrating partial effects of single miRNAs on cancer-specific survival for present 167 study cohort (n = 54). The baseline represents median relative expression for each miRNA (miR-21 = 8.34 Δ Ct, 168 miR-126 = 4.0 Δ Ct, miR-221 = 1.3 Δ Ct). Blue line represents minimum and brown line the maximum relative 169 expression of each miRNA in present study cohort. Other expression levels were chosen randomly (1.0 ΔCt 170 steps). (d) Forest plot representing log Hazard Ratios (HR) from multivariate Cox regression of miR-21, miR-171 126, miR-221, Fuhrman Grade (Fuhrman) and nodal status (N-Status) for cancer-related death (CRD). p values 172 were computed using the chi-squared test. 173

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

8 of 13

175

3.3. Kaplan Meier Analyses for single miR expression and the Risk Classifier

To investigate the prognostic transferability of single miRNAs, survival analyses using the cutoffs from Vergho et al. [10] were performed. Both, miR-21 and miR-126 showed a strong predictive 177 significance in the Kaplan-Meier survival analysis (Fig. 4a, b). However, differences regarding CSS 178 of miR-221 high vs. low expressing tumor specimens (Fig. 4c) did not reach statistical significance (p 179 = 0.25). 180

To validate the predictive potential of the risk classifier (Fig. 4d), the established cut-off level of 181 18.7 Δ Ct (\geq 18.7 Δ Ct = unfavorable subgroup, < 18.7 Δ Ct = favorable subgroup) was used to stratify 182 the validation cohort consisting of n = 54 ccRCC^{IVC} tissue samples. Out of 13 CRD cases, the classifier correctly identified 12 patients who suffered from CRD as members of the unfavorable subgroup 184 (92.3%; \geq 18.7 Δ Ct). Overall, a sensitivity of 92.3% (Cl 95%: 62.1% – 99.6%) and a specificity of 185 61.0% (Cl 95%: 44.5% – 75.4%) were reached. Difference in 5-years and 10-years CSS was 100% 186 vs. 70% and 94% vs. 31% between the favorable and the unfavorable subgroup, respectively. 187



Figure 4. Kaplan Meier survival analysis for CSS for external independent $ccRCC^{IVC}$ (n = 54) cohort from Regensburg stratified by miR-21 (a), miR-126 (b) and miR-221 (c) expression levels. (d) Combined miR-based risk188classifier (miR-21, -126, -221) using identical cut-offs and weights from a previous publication [10]. p values from190log-rank tests are shown within each plot.191

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

4. Discussion

ccRCCs infiltrating the inferior vena cava represent a clinically relevant high-risk subgroup. Still, 194 there is substantial clinical heterogeneity within this distinct subgroup - and biomarkers are needed 195 to assess the individual risk of progression. In general, adjuvant therapy with tyrosine kinase inhibitors 196 (TKI) or immune checkpoint blockers could be a promising therapeutic option after nephrectomy – 197 especially for patients suffering from high-risk RCC. However, European kidney cancer guidelines 198 currently do not contain strong recommendations towards adjuvant therapies due to the mixed out-199 come in clinical trials [24]. For the TKI sunitinib, one trial displayed improved disease-free survival 200 (DFS) for patients – while showing no significant differences in overall survival (OS) [25]. Additionally, 201 another phase 3 trial did not detect significant survival effects for adjuvant sunitinib or sorafenib in 202 nonmetastatic high-risk renal cell carcinoma [26]. Due to the sobering TKI results, research efforts 203 were mainly shifted towards immune checkpoint blockers. For the PD-1 (Programmed Cell Death 204 Protein 1) inhibitor pembrolizumab, KEYNOTE-564 trial detected improved progression-free survival 205 (PFS) in an adjuvant setting after nephrectomy [27]. 206

4.1. Evaluating a miR-based Risk Classifier for RCC with Infiltration of the Vena Cava

To estimate the individual risk of patients suffering from ccRCC^{IVC}, members of our research 208 group have established a risk classifier based on the tissue expression of miR-21, miR-126, and miR-209 221 [10]. Former cohort contained tumor tissue of n = 37 patients undergoing surgery at the University 210 Hospital of Würzburg, Germany. In this study, we externally validated the prognostic potential of the 211 miR-based risk classifier. Therefore, we examined an independent cohort of ccRCC^{IVC} from the Uni-212 versity of Regensburg, Germany (n = 56). To test the transferability and usability of the classifier 213 within an external tissue cohort, we applied identical cut-off values and weights as in the previous 214 pilot study. 215

Regarding clinicopathological characteristics of our study cohort, low miR-126 expression was 216 significantly associated with a positive lymphonodal status at time of surgery. Moreover, occurrence 217 of metastases during follow-up was significantly associated with higher miR-21 and lower miR-126 218 levels. Tumor tissue from patients suffering from CRD was also characterized by a significant upreg-219 ulation of miR-21 and a downregulation of miR-126. Within univariate cox regression, miR-21 and 220 miR-126 showed prognostic significance regarding cancer-specific survival (CSS). Lower levels of 221 miR-221 in tumor tissue and its association with CRD did not reach statistical significance. Beyond 222 miR expression, Fuhrman grade, lymphonodal status and occurrence of metastasis emerged as prog-223 nostically relevant. Next, we added a multivariate Cox regression for the three miR candidates. Again, 224 this study identified miR-21 and miR-126 expression to significantly impact CRD. Kaplan Meier anal-225 yses based on cut-off values determined previously by Vergho et al. [10] confirmed the significant 226 influence of miR-21 as well as miR-126 expression levels on CSS. Finally, applying the miR-based 227 classifier using identical cut-off values and weights split patients in two groups. 228

Of note, the classifier nearly stratified the study cohort in two halves – with n = 26 patients belonging to the favorable and n = 28 patients belonging to the unfavorable subgroup. Regarding the substantial difference in CSS between both groups, adjuvant therapies appear promising especially for the unfavorable subgroup of ccRCC^{IVC} patients.

4.2. Functional Roles of miR-21, miR-126, and miR-221 in Cancer

After confirming the prognostic potential of the miR classifier using the validation cohort from 234 Regensburg, we were interested in previously reported functions of these miRs in RCC and other 235 malignancies. For miR-21, several researchers demonstrated oncogenic effects in various cancers, 236 including RCC [28,29]. Among the prominent miR-21 target genes are key players of apoptosis induction like PDCD4 (Programmed Cell Death 4) [30] and genes like PTEN (Phosphatase and Tensin 238 Homolog) [28]. Latter is an established tumor suppressor gene best known for regulating PI3K/Akt 239 signaling. In contrast to miR-21, miR-126 acts as a tumor suppressor in tumor tissue, e. g. by targeting 240

207

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

ROCK1 (Rho Associated Coiled-Coil Containing Protein Kinase 1) [31] and VEGFA (Vascular Endo-241 thelial Growth Factor A) [32]. For miR-221, oncogenic versus protective functions appear to depend 242 on the underlying cancer entity, as researchers demonstrated both roles [33-35]. For RCC, a down-243 regulation of miR-221 appears well in line with previous publications. Specifically, miR-221 is reported 244 to regulate KDR (Kinase Insert Domain Receptor) - also known as VEGFR2 (Vascular Endothelial 245 Growth Factor Receptor 2) – in ccRCC [36] and prostate cancer [37], thereby regulating the sensitivity 246 towards sunitinib. In summary, among diverse tumorigenic functions of these miRs, all three candi-247 dates prominently influence angiogenesis-related pathways (so-called AngiomiRs) [38,39]. Given that 248 not all ccRCCs depend on angiogenic signaling to the same degree [40], it is tempting to assume that 249 the unfavorable subgroup identified by our risk classifier could benefit from adjuvant anti-angiogenic 250 therapy. 251

4.3. Limitations and Future Directions

Our study has several limitations. Leaving aside the definite RCC subgroup investigated here, 253 sample size of our study is relatively small. Moreover, we purposely did not adjust cut-off values and 254 individual miR weights determined previously in order to check the transferability of the risk classifier 255 to external tissue cohorts. More research - ideally in a prospective setting - could further validate the 256 risk classifier in a clinical setup and elucidate whether sub-classification of ccRCC^{IVC} is able to identify 257 patients most susceptible towards adjuvant therapy. 258

5. Conclusions

While RCC extending into the inferior vena cava represents a high-risk setting, there is still sub-260 stantial clinical heterogeneity within this patient subgroup. Previously, Vergho et al. established a 261 miR-based risk classifier - containing miR-21, miR-126 and miR-221 expression - which significantly 262 predicted CSS for patients from this subgroup. To validate this classifier, we examined its impact on 263 an external and independent patient cohort. Using identical cut-off values for single miRs and identical 264 weights within the classifier, we confirmed a highly significant risk stratification within the new cohort. 265 Patients with an unfavorable constellation according to the miR-based classifier could especially ben-266 efit from adjuvant therapy and continuous follow-up examinations. 267

Author Contributions: Conceptualization, M.Ko., M.Kr., B.K., D.V. and C.K.; methodology, M.Kr., 268 B.K., D.V. and C.K.; software, M.Ko., S.K. and B.K.; validation, M.Kr., M.B., J.B., H.K., D.V., B.K. and 269 C.K.; formal analysis, M.Ko., S.K. and C.K.; investigation, M.Ko., M.Kr., W.O., J.B., S.K., B.K. and 270 C.K; resources, J.B. and B.K.; data curation, M.Ko., B.K. and C.K.; writing-M.Kr., M.Ko., J.B., B.K. 271 and C.K.; writing-review and editing, M.Ko., M.Kr., M.B., H.K., R.B., W.O., J.B., S.K., D.V., B.K. and 272 C.K.; visualization, M.Ko. and M.Kr.; supervision, M.B., H.K., R.B., W.O., D.V., B.K. and C.K.; project 273 administration, M.Kr., B.K. and C.K.; funding acquisition, M.B. and H.K. 274

Funding: Markus Krebs was funded by a personal grant from Else-Kröner-Foundation (Else Kröner 275 Integrative Clinician Scientist College for Translational Immunology, University Hospital Würzburg, 276 Germany). 277

Institutional Review Board Statement: All procedures performed in studies involving human par-278 ticipants comply with the ethical standards laid down in the latest declaration of Helsinki of the World 279 Medical Association. The study was approved by the local Ethics Committees (Regensburg: Nr. 280 08/108, Würzburg: Nr. 136/08). All involved patients gave their written and informed consent for the 281 publication of their anonymized cases. 282

Informed Consent Statement: Informed consent was obtained from all subjects involved in the 283 study. 284

Data Availability Statement: All data produced in the present study are available upon reasonable request to the authors.	285 286
Conflicts of Interest: The authors declare no conflict of interest.	287
References	288
1. Ljungberg, B.; Stenling, R.; Osterdahl, B.; Farrelly, E.; Aberg, T.; Roos, G. Vein Invasion in Renal Cell	289
Carcinoma: Impact on Metastatic Behavior and Survival. Journal of Urology 1995, 154, 1681-1684,	290
doi:10.1016/S0022-5347(01)66749-1.	291
2. Hoehn, W.; Hermanek, P. Invasion of Veins in Renal Cell Carcinoma -Frequency, Correlation and	292
Prognosis. Eur Urol 1983, 9, 276–280, doi:10.1159/000474103.	293
3. Novick, A.C.; Cosgrove, D.M. Surgical Approach for Removal of Renal Cell Carcinoma Extending into the	294
Vena Cava and the Right Atrium. Journal of Urology 1980, 123, 947–950, doi:10.1016/S0022-5347(17)56207-2.	295
4. Haferkamp, A.; Bastian, P.J.; Jakobi, H.; Pritsch, M.; Pfitzenmaier, J.; Albers, P.; Hallscheidt, P.; Müller,	296
S.C.; Hohenfellner, M. Renal Cell Carcinoma With Tumor Thrombus Extension Into the Vena Cava: Prospective	297
Long-Term Followup. Journal of Urology 2007, 177, 1703–1708, doi:10.1016/j.juro.2007.01.039.	298
5. Blute, M.L.; Leibovich, B.C.; Lohse, C.M.; Cheville, J.C.; Zincke, H. The Mayo Clinic Experience with	299
Surgical Management, Complications and Outcome for Patients with Renal Cell Carcinoma and Venous Tumour	300
Thrombus. BJU Int 2004, 94, 33–41, doi:10.1111/j.1464-410X.2004.04897.x.	301
6. Vergho, D.C.; Loeser, A.; Kocot, A.; Spahn, M.; Riedmiller, H. Tumor Thrombus of Inferior Vena Cava in	302
Patients with Renal Cell Carcinoma – Clinical and Oncological Outcome of 50 Patients after Surgery. BMC Res	303
Notes 2012, 5, 264, doi:10.1186/1756-0500-5-264.	304
7. Haddad, A.Q.; Wood, C.G.; Abel, E.J.; Krabbe, LM.; Darwish, O.M.; Thompson, R.H.; Heckman, J.E.;	305
Merril, M.M.; Gayed, B.A.; Sagalowsky, A.I.; et al. Oncologic Outcomes Following Surgical Resection of Renal	306
Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary	307
Multicenter Cohort. Journal of Urology 2014, 192, 1050–1056, doi:10.1016/j.juro.2014.03.111.	308
8. Klatte, T.; Pantuck, A.J.; Riggs, S.B.; Kleid, M.D.; Shuch, B.; Zomorodian, N.; Kabbinavar, F.F.; Belldegrun,	309
A.S. Prognostic Factors for Renal Cell Carcinoma With Tumor Thrombus Extension. Journal of Urology 2007,	310
178, 1189–1195, doi:10.1016/j.juro.2007.05.134.	311
9. Berczi, A.; Flasko, T.; Szerafin, T.; Thomas, B.; Bacso, Z.; Berczi, C. Surgical Management and Outcome	312
of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. Urol Int 2017, 99, 267-271,	313
doi:10.1159/000464108.	314
10. Vergho, D.C.; Kneitz, S.; Kalogirou, C.; Burger, M.; Krebs, M.; Rosenwald, A.; Spahn, M.; Löser, A.; Kocot,	315
A.; Riedmiller, H.; et al. Impact of MiR-21, MiR-126 and MiR-221 as Prognostic Factors of Clear Cell Renal Cell	316
Carcinoma with Tumor Thrombus of the Inferior Vena Cava. PLoS ONE 2014, 9, e109877,	317
doi:10.1371/journal.pone.0109877.	318
11. Spachmann, P.J.; Breyer, J.; Kalogirou, C.; Lausenmeyer, EM.; Weber, F.; Prohaska, S.; Denzinger, S.;	319
Burger, M.; Kübler, H.; Otto, W.; et al. Impact of E-Cadherin and β-Catenin as Prognostic Factor in Renal Cell	320
Carcinoma with Tumor Thrombus of the Vena Cava. Urol Int 2019, 102, 413–420, doi:10.1159/000497279.	321
12. Ambros, V. MicroRNAs. Cell 2001, 107, 823–826, doi:10.1016/S0092-8674(01)00616-X.	322
13. Esquela-Kerscher, A.; Slack, F.J. Oncomirs — MicroRNAs with a Role in Cancer. <i>Nat Rev Cancer</i> 2006 ,	323
6, 259–269, doi:10.1038/nrc1840.	324

14. Kong, Y.W.; Ferland-McCollough, D.; Jackson, T.J.; Bushell, M. MicroRNAs in Cancer Management. The 325

Lancet Oncology 2012 , <i>1</i> 3, e249–e258, doi:10.1016/S1470-2045(12)70073-6.	326
15. Zaman, M.S.; Shahryari, V.; Deng, G.; Thamminana, S.; Saini, S.; Majid, S.; Chang, I.; Hirata, H.; Ueno,	327
K.; Yamamura, S.; et al. Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival. PLoS	328
<i>ONE</i> 2012 , 7, e31060, doi:10.1371/journal.pone.0031060.	329
16. Vergho, D.; Kneitz, S.; Rosenwald, A.; Scherer, C.; Spahn, M.; Burger, M.; Riedmiller, H.; Kneitz, B.	330
Combination of Expression Levels of MiR-21 and MiR-126 Is Associated with Cancer-Specific Survival in Clear-	331
Cell Renal Cell Carcinoma. BMC Cancer 2014, 14, 25, doi:10.1186/1471-2407-14-25.	332
17. Spadaccino, F.; Gigante, M.; Netti, G.S.; Rocchetti, M.T.; Franzin, R.; Gesualdo, L.; Castellano, G.;	333
Stallone, G.; Ranieri, E. The Ambivalent Role of MiRNAs in Carcinogenesis: Involvement in Renal Cell	334
Carcinoma and Their Clinical Applications. Pharmaceuticals 2021, 14, 322, doi:10.3390/ph14040322.	335
18. Davidson-Pilon, C. Lifelines: Survival Analysis in Python. JOSS 2019, 4, 1317, doi:10.21105/joss.01317.	336
19. McKinney, W. Data Structures for Statistical Computing in Python. Proceedings of the 9th Python in	337
Science Conference 2010, 56–61, doi:10.25080/Majora-92bf1922-00a.	338
20. Hunter, J.D. Matplotlib: A 2D Graphics Environment. Computing in Science & Engineering 2007, 9, 90-	339
95, doi:10.1109/MCSE.2007.55.	340
21. SciPy 1.0 Contributors; Virtanen, P.; Gommers, R.; Oliphant, T.E.; Haberland, M.; Reddy, T.; Cournapeau,	341
D.; Burovski, E.; Peterson, P.; Weckesser, W.; et al. SciPy 1.0: Fundamental Algorithms for Scientific Computing	342
in Python. Nat Methods 2020, 17, 261–272, doi:10.1038/s41592-019-0686-2.	343
22. Vergho, D.C.; Kneitz, S.; Kalogirou, C.; Burger, M.; Krebs, M.; Rosenwald, A.; Spahn, M.; Löser, A.; Kocot,	344
A.; Riedmiller, H.; et al. Impact of MiR-21, MiR-126 and MiR-221 as Prognostic Factors of Clear Cell Renal Cell	345
Carcinoma with Tumor Thrombus of the Inferior Vena Cava. PLoS One 2014, 9, e109877,	346
doi:10.1371/journal.pone.0109877.	347
23. Lossos, I.S.; Czerwinski, D.K.; Alizadeh, A.A.; Wechser, M.A.; Tibshirani, R.; Botstein, D.; Levy, R.	348
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. N Engl J Med	349
2004, 350, 1828–1837, doi:10.1056/NEJMoa032520.	350
24. Bedke, J.; Albiges, L.; Capitanio, U.; Giles, R.H.; Hora, M.; Lam, T.B.; Ljungberg, B.; Marconi, L.; Klatte,	351
T.; Volpe, A.; et al. 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant	352
Pembrolizumab for Renal Cell Carcinoma. European Urology 2022, 81, 134-137,	353
doi:10.1016/j.eururo.2021.11.022.	354
25. Ravaud, A.; Motzer, R.J.; Pandha, H.S.; George, D.J.; Pantuck, A.J.; Patel, A.; Chang, YH.; Escudier,	355
B.; Donskov, F.; Magheli, A.; et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N	356
Engl J Med 2016, 375, 2246–2254, doi:10.1056/NEJMoa1611406.	357
26. Haas, N.B.; Manola, J.; Uzzo, R.G.; Flaherty, K.T.; Wood, C.G.; Kane, C.; Jewett, M.; Dutcher, J.P.; Atkins,	358
M.B.; Pins, M.; et al. Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma	359
(ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial. Lancet 2016, 387,	360
2008–2016, doi:10.1016/S0140-6736(16)00559-6.	361
27. Choueiri, T.K.; Tomczak, P.; Park, S.H.; Venugopal, B.; Ferguson, T.; Chang, YH.; Hajek, J.; Symeonides,	362
S.N.; Lee, J.L.; Sarwar, N.; et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl	363
<i>J Med</i> 2021 , <i>385</i> , 683–694, doi:10.1056/NEJMoa2106391.	364
28. Kalogirou, C.; Schäfer, D.; Krebs, M.; Kurz, F.; Schneider, A.; Riedmiller, H.; Kneitz, B.; Vergho, D.	365
Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on MiR-21-Mediated PTEN Expression.	366
<i>Urol Int</i> 2016 , <i>96</i> , 106–115, doi:10.1159/000441011.	367

29. Bautista-Sánchez, D.; Arriaga-Canon, C.; Pedroza-Torres, A.; De La Rosa-Velázquez, I.A.; González-368 Barrios, R.; Contreras-Espinosa, L.; Montiel-Manríguez, R.; Castro-Hernández, C.; Fragoso-Ontiveros, V.; 369 Álvarez-Gómez, R.M.; et al. The Promising Role of MiR-21 as a Cancer Biomarker and Its Importance in RNA-370 Based Therapeutics. Molecular Therapy - Nucleic Acids 2020, 20, 409-420, doi:10.1016/j.omtn.2020.03.003. 371 30. Li, X.; Xin, S.; He, Z.; Che, X.; Wang, J.; Xiao, X.; Chen, J.; Song, X. MicroRNA-21 (MiR-21) Post-372 Transcriptionally Downregulates Tumor Suppressor PDCD4 and Promotes Cell Transformation, Proliferation, 373 and Metastasis in Renal Cell Carcinoma. Cell Physiol Biochem 2014, 33, 1631–1642, doi:10.1159/000362946. 374 Zhang, G.-M.; Luo, L.; Ding, X.-M.; Dong, D.-H.; Li, B.; Ma, X.-C.; Sun, L.-J. MicroRNA-126 Inhibits Tumor 31. 375 Cell Invasion and Metastasis by Downregulating ROCK1 in Renal Cell Carcinoma. Molecular Medicine Reports 376 2016. 13, 5029-5036, doi:10.3892/mmr.2016.5160. 377 32. Sasahira, T.; Kurihara, M.; Bhawal, U.K.; Ueda, N.; Shimomoto, T.; Yamamoto, K.; Kirita, T.; Kuniyasu, H. 378 Downregulation of MiR-126 Induces Angiogenesis and Lymphangiogenesis by Activation of VEGF-A in Oral 379 Cancer. Br J Cancer 2012, 107, 700-706, doi:10.1038/bjc.2012.330. 380 33. Garofalo, M.; Quintavalle, C.; Romano, G.; M. Croce, C.; Condorelli, G. MiR221/222 in Cancer: Their Role 381 in Tumor Progression and Response to Therapy. CMM 2012, 12, 27-33, doi:10.2174/156652412798376170. 382 Li, F.; Xu, J.-W.; Wang, L.; Liu, H.; Yan, Y.; Hu, S.-Y. MicroRNA-221-3p Is up-Regulated and Serves as a 34. 383 Potential Biomarker in Pancreatic Cancer. Artificial Cells, Nanomedicine, and Biotechnology 2018, 46, 482-487, 384 doi:10.1080/21691401.2017.1315429. 385 35. Kneitz, B.; Krebs, M.; Kalogirou, C.; Schubert, M.; Joniau, S.; van Poppel, H.; Lerut, E.; Kneitz, S.; Scholz, 386 C.J.; Ströbel, P.; et al. Survival in Patients with High-Risk Prostate Cancer Is Predicted by MiR-221, Which 387 Regulates Proliferation, Apoptosis, and Invasion of Prostate Cancer Cells by Inhibiting IRF2 and SOCS3. Cancer 388 Res. 2014, 74, 2591–2603, doi:10.1158/0008-5472.CAN-13-1606. 389 36. Khella, H.W.Z.; Butz, H.; Ding, Q.; Rotondo, F.; Evans, K.R.; Kupchak, P.; Dharsee, M.; Latif, A.; Pasic, 390 M.D.; Lianidou, E.; et al. MiR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell 391 Carcinoma. Mol. Ther. 2015, 23, 1748-1758, doi:10.1038/mt.2015.129. 392 37. Krebs, M.; Solimando, A.G.; Kalogirou, C.; Marquardt, A.; Frank, T.; Sokolakis, I.; Hatzichristodoulou, G.; 393 Kneitz, S.; Bargou, R.; Kübler, H.; et al. MiR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate 394 Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. JCM 2020, 9, 670, 395 doi:10.3390/jcm9030670. 396 38. Salinas-Vera, Y.M.; Marchat, L.A.; Gallardo-Rincón, D.; Ruiz-García, E.; Astudillo-De La Vega, H.; 397 Echavarría-Zepeda, R.; López-Camarillo, C. AngiomiRs: MicroRNAs Driving Angiogenesis in Cancer (Review). 398 Int J Mol Med 2019, 43, 657-670, doi:10.3892/ijmm.2018.4003. 399 Wang, S.; Olson, E.N. AngiomiRs-Key Regulators of Angiogenesis. Current Opinion in Genetics & 39. 400 Development 2009, 19, 205-211, doi:10.1016/j.gde.2009.04.002. 401 Marquardt, A.; Solimando, A.G.; Kerscher, A.; Bittrich, M.; Kalogirou, C.; Kübler, H.; Rosenwald, A.; 40 402 Bargou, R.; Kollmannsberger, P.; Schilling, B.; et al. Subgroup-Independent Mapping of Renal Cell Carcinoma-403 Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. Front. 404 Oncol. 2021, 11, 621278, doi:10.3389/fonc.2021.621278. 405 406